CN101342187B - Medicament composition for treating dysentery - Google Patents
Medicament composition for treating dysentery Download PDFInfo
- Publication number
- CN101342187B CN101342187B CN2008101962304A CN200810196230A CN101342187B CN 101342187 B CN101342187 B CN 101342187B CN 2008101962304 A CN2008101962304 A CN 2008101962304A CN 200810196230 A CN200810196230 A CN 200810196230A CN 101342187 B CN101342187 B CN 101342187B
- Authority
- CN
- China
- Prior art keywords
- micronomicin
- lincomycin
- patient
- dysentery
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a medicinal compound for curing dysentery, which contains the components with the following weight portions: 1.2 to 2.4 portions of lincomycin and 0.12 to 0.24 portions of micronomicin. In use, lincomycin and micronomicin are mixed with glucose water or salt water and 0.005 to 0.01 weight portions of dexamethasone is added into the compound. When the patient has serious abdominal pain, 0.005 to 0.01 weight portions of muriatic racemic antisodamine alkali is added into the compound. The present invention with the matched use of lincomycin and micronomicin has treated nearly 100 cases of patients and obtains excellent curing effect. Even for severe cases, the recovery is made by only twice transfusion, thus greatly reducing the pain of the patient and saving the medical expense of the patient.
Description
Technical field:
This utility model relates to a kind of Western medicine for the treatment of dysentery.
Background technology:
Bacillary dysentery is a kind of commonly encountered diseases in the digestive system disease, is a kind of infectious disease of the digestive tract, and with containing pus and blood in stomachache, many, the feces of defecation frequency, severe patient is also with hyperpyrexia during patient's defecation.Antibacterial in its feces is given other people by polluted source, food and hand-borne infection.This disease two season of autumn in summer sickness rate higher, the patient suffering is bigger, immunity generally reduces after being ill.At present, the medical personnel is when treatment dysentery, and general giving obeyed furazolidone, sulphonamides, berberine etc., or, generally speaking, all to infuse and to cure more than three days by Western medicine such as intravenous injection chloromycetin, gentamycins, to the heavier person of some state of an illness, need a week even longer time.Because treatment time is long, patient is agonizing.
Summary of the invention:
The technical problem to be solved in the present invention provides a kind of pharmaceutical composition for the treatment of dysentery, and therapeutic effect is good, short treating period.
The present invention solves by the following technical programs:
A kind of pharmaceutical composition for the treatment of dysentery, characteristics are to comprise lincomycin 1.2-2.4 part, micronomicin 0.12-0.24 part by weight, during use, it are mixed with G/W or saline.
When patient's stomachache is heavier, in compositions, add Hydrochloric acid raceanisodamine again, it adds weight portion is 0.005-0.01 part.Add dexamethasone in compositions again, it adds weight portion is 0.005-0.01 part.
Lincomycin is mainly used in staphylococcus, streptococcus, the microbial respiratory tract infection of pneumonia streptococcus, osteomyelitis, joint and soft tissue infection, biliary tract infection and septicemia.Also can use some anaerobic infections.Be to suppress protein of bacteria to synthesize in the main machine.To the similar erythromycin of the antibacterial action of gram positive bacteria, sensitive organism can comprise streptococcus pneumoniae, micrococcus scarlatinae, viridans streptococci, staphylococcus aureus, diphtheria corynebacterium etc.Anaerobe comprises Bacteroides, Fusobacterium, propionibacterium, Eubacterium, bacillus bifidus, peptostreptococcus, most dyspepsiacoccus, bacillus perfringens, clostridium tetani and some actinomycetes etc. to this product sensitivity person.It is all insensitive that streptococcus faecalis, some clostruidium, slave are blocked bacterium, yeast, fungus and virus.
Micronomicin is mainly used in respiratory tract, urinary tract, abdominal cavity and the trauma infection contamination that gram negative bacillis such as escherichia coli, klebsiella bacillus, Bacillus proteus, Enterobacter, serratia marcecens, bacillus pyocyaneus cause, also can be used for septicemia.
Because the known performance of lincomycin, for a long time, nobody is used for the treatment of dysentery with lincomycin, and also nobody is used treatment dysentery with lincomycin and micronomicin.
The present invention is used lincomycin and micronomicin, and the treatment through to nearly 100 routine patients has obtained extraordinary therapeutic effect, even the patient with severe symptoms only needs twice transfusion to fully recover, alleviated patient's misery greatly, simultaneously, also saved patient's medical expense.The present invention not only has better therapeutic effect to dysentery, and enteritis is had better therapeutic effect equally.
The specific embodiment:
Embodiment 1
A kind of pharmaceutical composition for the treatment of dysentery comprises 1.8 parts of lincomycins, 0.18 part of micronomicin by weight, during use, with mix homogeneously in the G/W of 500 parts of its addings.Add dexamethasone in compositions again, it adds weight portion is 0.01 part.As patient during with pain, in compositions, add Hydrochloric acid raceanisodamine again, it adds weight portion is 0.01 part.
Embodiment 2
A kind of pharmaceutical composition for the treatment of dysentery comprises 1.2 parts of lincomycins, 0.12 part of micronomicin by weight, during use, with mix homogeneously in the G/W of 200 parts of its addings.Add dexamethasone in compositions again, it adds weight portion is 0.005 part.As patient during with pain, in compositions, add Hydrochloric acid raceanisodamine again, it adds weight portion is 0.005 part.
A kind of pharmaceutical composition for the treatment of dysentery comprises 2.4 parts of lincomycins, 0.24 part of micronomicin by weight, during use, with mix homogeneously in the G/W of 700 parts of its addings.Add dexamethasone in compositions again, it adds weight portion is 0.01 part.As patient during with pain, in compositions, add Hydrochloric acid raceanisodamine again, it adds weight portion is 0.01 part.
Model case:
Liu, man, 20 years old, clinical manifestation: body temperature 40.0 degree, with stomachache, the tenesmus sense is arranged, spirit is very poor, arrange red white mucus, surplus day defecation 20 time, with lincomycin 1.8 grams, micronomicin 0.18 gram, 10 milligrams of dexamethasone, 10 milligrams of Hydrochloric acid raceanisodamines, be mixed in 500 milliliter of 5% G/W, venous transfusion is once cured.
Honest and just certain, woman, 58 years old, clinical manifestation: body temperature 40.2 degree, she arranges red white mucus, surplus day defecation ten time, with stomachache.With lincomycin 1.8 grams, micronomicin 0.18 gram, 10 milligrams of dexamethasone, 10 milligrams of Hydrochloric acid raceanisodamines are mixed in 500 milliliter of 5% G/W, and venous transfusion is once cured.
Liu, man, 18 years old, clinical manifestation: body temperature 40.0 degree, arrange red white mucus, surplus day defecation ten time, with stomachache.With lincomycin 1.8 grams, micronomicin 0.18 gram, 10 milligrams of dexamethasone, 10 milligrams of Hydrochloric acid raceanisodamines are mixed in 500 milliliter of 5% G/W, and venous transfusion is once cured.
Leaf, man, 61 years old, clinical manifestation: body temperature 40.2 degree, arrange red white mucus, surplus day defecation ten time, with stomachache.With lincomycin 1.8 grams, micronomicin 0.18 gram, 10 milligrams of dexamethasone, 10 milligrams of Hydrochloric acid raceanisodamines are mixed in 500 milliliter of 5% G/W, and venous transfusion is once cured.
Claims (4)
1. pharmaceutical composition for the treatment of dysentery is characterized in that: be made up of following medicine by weight:
Lincomycin 1.2-2.4 part, micronomicin 0.12-0.24 part during use, are mixed it with G/W or saline.
2. pharmaceutical composition for the treatment of dysentery is characterized in that: be made up of following medicine by weight:
Lincomycin 1.2-2.4 part, micronomicin 0.12-0.24 part, Hydrochloric acid raceanisodamine 0.005-0.01 part during use, are mixed it with G/W or saline.
3. pharmaceutical composition for the treatment of dysentery is characterized in that: be made up of following medicine by weight:
Lincomycin 1.2-2.4 part, micronomicin 0.12-0.24 part, dexamethasone 0.005-0.01 part during use, are mixed it with G/W or saline.
4. pharmaceutical composition for the treatment of dysentery is characterized in that: be made up of following medicine by weight:
Lincomycin 1.2-2.4 part, micronomicin 0.12-0.24 part, Hydrochloric acid raceanisodamine 0.005-0.01 part, dexamethasone 0.005-0.01 part during use, are mixed it with G/W or saline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101962304A CN101342187B (en) | 2008-08-21 | 2008-08-21 | Medicament composition for treating dysentery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101962304A CN101342187B (en) | 2008-08-21 | 2008-08-21 | Medicament composition for treating dysentery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101342187A CN101342187A (en) | 2009-01-14 |
| CN101342187B true CN101342187B (en) | 2010-10-13 |
Family
ID=40244378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101962304A Expired - Fee Related CN101342187B (en) | 2008-08-21 | 2008-08-21 | Medicament composition for treating dysentery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101342187B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106619682A (en) * | 2016-12-23 | 2017-05-10 | 郑州仁宏医药科技有限公司 | Pharmaceutical composition for treating porcine diarrhea |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887290A (en) * | 2005-06-30 | 2007-01-03 | 信谊药厂 | Lincomycin hydrochloride composition and its prepn |
| CN101015561A (en) * | 2007-02-13 | 2007-08-15 | 天津生机集团有限公司 | Compound genticin-micronomicin injection, preparing method and use thereof |
-
2008
- 2008-08-21 CN CN2008101962304A patent/CN101342187B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887290A (en) * | 2005-06-30 | 2007-01-03 | 信谊药厂 | Lincomycin hydrochloride composition and its prepn |
| CN101015561A (en) * | 2007-02-13 | 2007-08-15 | 天津生机集团有限公司 | Compound genticin-micronomicin injection, preparing method and use thereof |
Non-Patent Citations (5)
| Title |
|---|
| CN 1887290 A,摘要. |
| 刘锦华 等.小诺霉素的药理与临床.湖南药学8 5.1991,8(5),319-320. |
| 刘锦华等.小诺霉素的药理与临床.湖南药学8 5.1991,8(5),319-320. * |
| 薛伟先 等.合理应用盐酸林可霉素.职业与健康16 4.2000,16(4),83. |
| 薛伟先等.合理应用盐酸林可霉素.职业与健康16 4.2000,16(4),83. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101342187A (en) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507270A5 (en) | ||
| CN103360464A (en) | Polypeptide, DNA molecule encoding polypeptide, vector, preparation method and application thereof | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| Morse et al. | Once weekly intraperitoneal therapy for gram-positive peritonitis | |
| CN101342187B (en) | Medicament composition for treating dysentery | |
| Davrnovich et al. | THE PROGRAMME FOR THE COMPREHENSIVE TREATMENT OF MAXILLOFACIAL PHLEGMONITIS PATIENTS WITH VIRAL HEPATITIS B | |
| CN102949397B (en) | Cefotaxime sodium and tazobactam sodium preparation for injection and preparing method thereof | |
| CN103083502A (en) | Drug for treating animal traumatic infection disease | |
| CN101023955A (en) | Medicine composition and use | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| Wang et al. | Bovine lactoferrin inhibits resistant Helicobacter pylori in vitro and protects gastric mucosal injury in vivo | |
| CN101244137B (en) | Medicament for treating pulmonitis, and high fever, lower fever, and preparation method | |
| CN103561735A (en) | Medicinal preparation ''RENESSANS'' having an antibacterial, anti-ulcerous and immuno-modulating action | |
| Kubota et al. | Campylobacter fetus subspecies fetus peritonitis in continuous ambulatory peritoneal dialysis | |
| Pines et al. | A comparison of pivampicillin and ampicillin in exacerbations of chronic bronchitis | |
| BR0318497A (en) | antibacterial drug compound comprising n-acetyl d-glucosamine | |
| Davis | Antimicrobial selection in practice. | |
| CN1098076C (en) | Oral linmerjing as one kind of powerful anti-bacterial medicine | |
| CN106668011A (en) | New application of vitamin C | |
| CN105168211B (en) | A kind of omeprazole sodium medicinal composition | |
| EP1417969B1 (en) | A pharmaceutical composition for the medical treatment of the benign prostatic hyperplasia, its preparation method and its therapeutical application | |
| RU2229301C1 (en) | Method for treating purulent-inflammatory diseases in case of diabetes mellitus | |
| JPS5835119A (en) | Immunological phagocytotic activator | |
| CN101574421A (en) | Medicament for treating leukemia and septicemia | |
| CN104758669A (en) | Traditional Chinese medicine composition for treating urinary tract infection in the type of excessive heat in small intestine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101013 Termination date: 20120821 |